Editorial. Discusses the use of surrogate markers in the design and implementation of critical trials for early approval of new drugs to combat HIV and for patient management. Conditions to consider in order to satisfy a formal definition of a surrogate marker; Value of surrogate markers in a drug approval process; Evaluation of CD4 count in persons receiving zidovudine.